Biomarkers of Alzheimer's Disease

Overview

Journal Neurobiol Dis

Specialty Neurology

Date 2008 Nov 18

PMID 19010417

Citations 69

Authors

Rebecca Craig-Schapiro

Anne M Fagan

David M Holtzman

Affiliations

Soon will be listed here.

Abstract

Although a battery of neuropsychological tests is often used in making a clinical diagnosis of Alzheimer's disease (AD), definitive diagnosis still relies on pathological evaluation at autopsy. The identification of AD biomarkers may allow for a less invasive and more accurate diagnosis as well as serve as a predictor of future disease progression and treatment response. Importantly, biomarkers may also allow for the identification of individuals who are already developing the underlying pathology of AD such as plaques and tangles yet who are not yet demented, i.e. "preclinical" AD. Attempts to identify biomarkers have included fluid and imaging studies, with a number of candidate markers showing significant potential. More recently, better reagent availability and novel methods of assessment have further spurred the search for biomarkers of AD. This review will discuss promising fluid and imaging markers to date.

Citing Articles

Identification of critical genes and drug repurposing targets in entorhinal cortex of Alzheimer's disease.

Hosseinpouri A, Sadegh K, Zarei-Behjani Z, Dehghan Z, Karbalaei R Neurogenetics. 2025; 26(1):27.

PMID: 39928227 DOI: 10.1007/s10048-025-00806-x.

Gut Microbiome in Alzheimer's Disease: from Mice to Humans.

Liang C, Pereira R, Zhang Y, Rojas O Curr Neuropharmacol. 2024; 22(14):2314-2329.

PMID: 39403057 PMC: 11451315. DOI: 10.2174/1570159X22666240308090741.

Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy.

Babic M, Banovic M, Berecic I, Banic T, Babic Leko M, Ulamec M J Clin Med. 2023; 12(15).

PMID: 37568462 PMC: 10419842. DOI: 10.3390/jcm12155060.

Gut microbiome composition may be an indicator of preclinical Alzheimer's disease.

Ferreiro A, Choi J, Ryou J, Newcomer E, Thompson R, Bollinger R Sci Transl Med. 2023; 15(700):eabo2984.

PMID: 37315112 PMC: 10680783. DOI: 10.1126/scitranslmed.abo2984.

Perspectives of diabetic retinopathy-challenges and opportunities.

Sivaprasad S, Sen S, Cunha-Vaz J Eye (Lond). 2022; 37(11):2183-2191.

PMID: 36494431 PMC: 10366207. DOI: 10.1038/s41433-022-02335-5.

References

Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K . Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol. 2000; 43(3):155-60. DOI: 10.1159/000008156. View

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B . Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001; 58(3):373-9. DOI: 10.1001/archneur.58.3.373. View

Hampel H, Teipel S, Padberg F, Haslinger A, Riemenschneider M, Schwarz M . Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. Brain Res. 1999; 823(1-2):104-12. DOI: 10.1016/s0006-8993(99)01146-4. View

Petrella J, Krishnan S, Slavin M, Tran T, Murty L, Doraiswamy P . Mild cognitive impairment: evaluation with 4-T functional MR imaging. Radiology. 2006; 240(1):177-86. DOI: 10.1148/radiol.2401050739. View

Rowe C, Ackerman U, Browne W, Mulligan R, Pike K, OKeefe G . Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7(2):129-35. DOI: 10.1016/S1474-4422(08)70001-2. View

de Leon M, George A, Golomb J, Tarshish C, Convit A, Kluger A . Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging. 1997; 18(1):1-11. DOI: 10.1016/s0197-4580(96)00213-8. View

Hu Y, Hosseini A, Kauwe J, Gross J, Cairns N, Goate A . Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clin Appl. 2010; 1(11):1373-84. DOI: 10.1002/prca.200600999. View

de Leon M, DeSanti S, Zinkowski R, Mehta P, Pratico D, Segal S . Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2005; 27(3):394-401. DOI: 10.1016/j.neurobiolaging.2005.07.003. View

Janus C, Pearson J, McLaurin J, Mathews P, Jiang Y, Schmidt S . A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2001; 408(6815):979-82. DOI: 10.1038/35050110. View

10.

Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers H . Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006; 129(Pt 11):3042-50. DOI: 10.1093/brain/awl279. View

11.

Chong J, Miller B, Ghanbari H . Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid. Life Sci. 1990; 47(13):1163-71. DOI: 10.1016/0024-3205(90)90177-s. View

12.

Rosler N, Wichart I, Jellinger K . Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transm (Vienna). 2001; 108(2):231-46. DOI: 10.1007/s007020170091. View

13.

Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, Moriguchi Y . The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage. 2005; 28(4):1014-21. DOI: 10.1016/j.neuroimage.2005.06.066. View

14.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

15.

DeKosky S, Ikonomovic M, Wang X, Farlow M, Wisniewski S, Lopez O . Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol. 2003; 53(1):81-90. DOI: 10.1002/ana.10414. View

16.

Johnson K, Gregas M, Becker J, Kinnecom C, Salat D, Moran E . Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62(3):229-34. DOI: 10.1002/ana.21164. View

17.

Price J, Morris J . Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45(3):358-68. DOI: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. View

18.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

19.

DeMattos R, Bales K, Parsadanian M, ODell M, Foss E, Paul S . Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002; 81(2):229-36. DOI: 10.1046/j.1471-4159.2002.00889.x. View

20.

Nielsen H, Minthon L, Londos E, Blennow K, Miranda E, Perez J . Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology. 2007; 69(16):1569-79. DOI: 10.1212/01.wnl.0000271077.82508.a0. View